(Reuters) – Seagen said on Wednesday its breast cancer therapy in combination with Roche’s Kadcyla helped extend the time patients lived without their disease progressing in a late-stage trial.
Pfizer Inc has agreed to acquire Seagen in a $43 billion deal to gain access to its targeted cancer therapies.
The therapy, Tukysa, chemically known as tucatinib, is approved in the United States to be used in combination with Roche’s Herceptin and Xeloda in patients whose cancer has worsened or spread despite at least one prior round of treatment.
Kadcyla belongs to a class of drugs antibody-drug conjugates (ADCs), which have been described as “guided-missile” cancer drugs.
(Reporting by Mariam Sunny in Bengaluru; Editing by Maju Samuel)
